Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “Vertex Pharmaceuticals” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 159
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 159 pipeline programs matching "Vertex Pharmaceuticals" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

159 results for “Vertex Pharmaceuticals” Back to intelligence hub

Search results

Page 5 of 7
  1. VX-765

    Vertex Pharmaceuticals (Australia) Pty.

    Partial Epilepsy

    phase 2 small molecule completed

    1 trial
  2. VX-765 Part A

    Vertex Pharmaceuticals (Australia) Pty.

    Epilepsy

    phase 2 small molecule terminated

    1 trial
  3. VX-770

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    3 trials
  4. VX-787

    Vertex Pharmaceuticals (Australia) Pty.

    Influenza Virus

    phase 2 small molecule completed

    1 trial
  5. VX-814

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule terminated

    1 trial
  6. VX-864

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha-1 Antitrypsin Deficiency

    phase 2 small molecule terminated

    1 trial
  7. VX-864

    Vertex Pharmaceuticals (Australia) Pty.

    Alpha1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial
  8. VX-950

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    2 trials
  9. VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 2 small molecule completed

    1 trial
  10. VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule active

    1 trial
  11. VX23-670-001

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy

    phase 2 small molecule active

    1 trial
  12. VX24-993-103

    Vertex Pharmaceuticals (Australia) Pty.

    Pain Associated With Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial
  13. biricodar dicitrate

    Vertex Pharmaceuticals (Australia) Pty.

    Lung Cancer

    phase 2 small molecule terminated

    1 trial
  14. telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C Virus Infection

    phase 2 small molecule terminated

    1 trial
  15. telaprevir or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial
  16. 14C-VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    1 trial
  17. ALS-002158

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 1 small molecule terminated

    1 trial
  18. ALS-002200

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 1 small molecule completed

    1 trial
  19. AVN-944 capsules for oral administration

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Leukemia

    phase 1 small molecule completed

    1 trial
  20. G060-A5

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 1 small molecule completed

    1 trial
  21. IXP

    Vertex Pharmaceuticals (Australia) Pty.

    Renal Impairment

    phase 1 small molecule completed

    1 trial
  22. IXP

    Vertex Pharmaceuticals (Australia) Pty.

    Focal Segmental Glomerulosclerosis (FSGS)

    phase 1 small molecule completed

    1 trial
  23. MP-424 (Telaprevir)

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial
  24. PegInterferon

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.